Bioxyne (ASX:BXNDA) Research & Development: A$0.07 Mil (TTM As of Dec. 2025)


ASX:BXNDA Bioxyne Ltd ASX:BXNDA
50 GF Score
Price A$0.95
GF Value A$0.69
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bioxyne Research & Development?

Bioxyne ASX:BXNDA -2.06% 50 Research & Development is A$0.07 Mil as of Dec. 2025. GuruFocus rates ASX:BXNDA with a GF Score™ of 50/100 and a GF Value™ of A$0.69 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bioxyne's Research & Development for the six months ended in Dec. 2025 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.07 Mil.

Bioxyne  (ASX:BXNDA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bioxyne Research & Development Related Terms

Bioxyne Research & Development Historical Data

* Premium members only.

The historical data trend for Bioxyne's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioxyne Research & Development Chart

Bioxyne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.00 0.00 0.72 0.18

Bioxyne Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.11 0.07 0.00
ASX:BXNDA
50GF Score
Bioxyne Ltd ASX:BXNDA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioxyne Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.07 Mil mean?
Bioxyne (ASX:BXNDA) has a Research & Development of A$0.07 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bioxyne and its competitors.
Is Bioxyne's Research & Development too high?
Bioxyne's current Research & Development is A$0.07 Mil. Overall, Bioxyne has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioxyne's Research & Development compare to KHC and GIS?
Bioxyne's Research & Development of A$0.07 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bioxyne and its competitors. Bioxyne's current Research & Development is A$0.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioxyne stock overvalued right now?
Based on GuruFocus' analysis, Bioxyne (ASX:BXNDA) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.95 — trading 37.7% above its estimated fair value. The current Research & Development is A$0.07 Mil. Bioxyne's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bioxyne (ASX:BXNDA), the current Research & Development is A$0.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioxyne (ASX:BXNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Bioxyne stock appears to be overvalued. The current stock price of A$0.95 is trading 37.7% above its estimated GF Value™ of A$0.69. GuruFocus considers Bioxyne to be Significantly Overvalued.

Key valuation signals for ASX:BXNDA:

  • Research & Development: A$0.07 Mil
  • GF Value™: A$0.69 vs. price of A$0.95 (37.7% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the ASX:BXNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioxyne Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
50GF Score

Get the complete analysis for ASX:BXNDA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.95
Price
A$0.69
GF Value